Ovarian cycle stage critically affects 21-gene recurrence scores in Mmtv-Pymt mouse mammary tumours

• Published in: BMC cancer Vol. 21; no. 1; pp. 1 - 736
• Main Authors: Bernhardt, Sarah M, Dasari, Pallave, Glynn, Danielle J, Woolford, Lucy, Moldenhauer, Lachlan M, Walsh, David, Townsend, Amanda R, Price, Timothy J, Ingman, Wendy V
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 26.06.2021; BioMed Central; BMC
• Subjects: Algorithms; Antigens; Biomarkers; Biopsy; Breast cancer; Cancer; Care and treatment; Chemotherapy; Development and progression; ErbB-2 protein; Estrogen receptors; Estrogens; Estrus; Gene expression; Genetic aspects; Genomics; Health aspects; Hormones; Identification and classification; Menstrual cycle; Menstruation; Microscopy; Mouse models; Oncogenes; Ovarian cycle; Ovaries; Predictive biomarkers; Premenopausal Breast cancer; Progesterone; Real time; Relapse; Transgenic animals; Tumors; Womens health; Australia
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-021-08496-y

Background The Oncotype DX 21-gene Recurrence Score is predictive of adjuvant chemotherapy benefit for women with early-stage, estrogen receptor (ER)-positive, HER2-negative breast cancer. In premenopausal women, fluctuations in estrogen and progesterone during the menstrual cycle impact gene expression in hormone-responsive cancers. However, the extent to which menstrual cycling affects the Oncotype DX 21-gene signature remains unclear. Here, we investigate the impact of ovarian cycle stage on the 21-gene signature using a naturally cycling mouse model of breast cancer. Methods ER-positive mammary tumours were dissected from naturally cycling Mmtv-Pymt mice at either the estrus or diestrus phase of the ovarian cycle. The Oncotype DX 21-gene signature was assessed through quantitative real time-PCR, and a 21-gene experimental recurrence score analogous to the Oncotype DX Recurrence Score was calculated. Results Tumours collected at diestrus exhibited significant differences in expression of 6 Oncotype DX signature genes (Ki67, Ccnb1, Esr1, Erbb2, Grb7, Bag1; p [less than or equai to] 0.05) and a significant increase in 21-gene recurrence score (21.8 [+ or -] 2.4; mean [+ or -] SEM) compared to tumours dissected at estrus (15.5 [+ or -] 1.9; p = 0.03). Clustering analysis revealed a subgroup of tumours collected at diestrus characterised by increased expression of proliferation- (p < 0.001) and invasion-group (p = 0.01) genes, and increased 21-gene recurrence score (p = 0.01). No correlation between ER, PR, HER2, and KI67 protein abundance measured by Western blot and abundance of mRNA for the corresponding gene was observed, suggesting that gene expression is more susceptible to hormone-induced fluctuation compared to protein expression. Conclusions Ovarian cycle stage at the time of tissue collection critically affects the 21-gene signature in Mmtv-Pymt murine mammary tumours. Further studies are required to determine whether Oncotype DX Recurrence Scores in women are similarly affected by menstrual cycle stage. Keywords: Premenopausal Breast cancer, Predictive biomarkers, Ovarian cycle, Genomics, Mouse models